305 related articles for article (PubMed ID: 33457427)
21. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
22. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
23. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
[TBL] [Abstract][Full Text] [Related]
24. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.
Sahin Ozkan H; Ugurlu MU; Yumuk PF; Kaya H
Pathol Oncol Res; 2020 Oct; 26(4):2733-2745. PubMed ID: 32681436
[TBL] [Abstract][Full Text] [Related]
26. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.
Hammerl D; Martens JWM; Timmermans M; Smid M; Trapman-Jansen AM; Foekens R; Isaeva OI; Voorwerk L; Balcioglu HE; Wijers R; Nederlof I; Salgado R; Horlings H; Kok M; Debets R
Nat Commun; 2021 Sep; 12(1):5668. PubMed ID: 34580291
[TBL] [Abstract][Full Text] [Related]
27. Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC).
Tokumaru Y; Oshi M; Murthy V; Tian W; Yan L; Angarita FA; Nagahashi M; Matsuhashi N; Futamura M; Yoshida K; Miyoshi Y; Takabe K
Am J Cancer Res; 2021; 11(11):5743-5755. PubMed ID: 34873491
[TBL] [Abstract][Full Text] [Related]
28. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
Tzikas AK; Nemes S; Linderholm BK
Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
[TBL] [Abstract][Full Text] [Related]
29. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.
Sui S; An X; Xu C; Li Z; Hua Y; Huang G; Sui S; Long Q; Sui Y; Xiong Y; Ntim M; Guo W; Chen M; Deng W; Xiao X; Li M
Theranostics; 2020; 10(26):11938-11949. PubMed ID: 33204321
[No Abstract] [Full Text] [Related]
30. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
31. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-34 contributes to poor prognosis in triple-negative breast cancer.
Kajihara N; Kitagawa F; Kobayashi T; Wada H; Otsuka R; Seino KI
Breast Cancer; 2020 Nov; 27(6):1198-1204. PubMed ID: 32578004
[TBL] [Abstract][Full Text] [Related]
33. Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis.
Okano M; Oshi M; Butash AL; Katsuta E; Tachibana K; Saito K; Okayama H; Peng X; Yan L; Kono K; Ohtake T; Takabe K
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461932
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
35. Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.
Sato K; Miura K; Tamori S; Akimoto K
Cancer Genomics Proteomics; 2024; 21(3):316-326. PubMed ID: 38670590
[TBL] [Abstract][Full Text] [Related]
36. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
37. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
Oliveira M; Saura C; Nuciforo P; Calvo I; Andersen J; Passos-Coelho JL; Gil Gil M; Bermejo B; Patt DA; Ciruelos E; de la Peña L; Xu N; Wongchenko M; Shi Z; Singel SM; Isakoff SJ
Ann Oncol; 2019 Aug; 30(8):1289-1297. PubMed ID: 31147675
[TBL] [Abstract][Full Text] [Related]
38. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC).
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Kalinski P; Endo I; Takabe K
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198125
[TBL] [Abstract][Full Text] [Related]
39. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
40. An overview of triple-negative breast cancer.
Kumar P; Aggarwal R
Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
